Tag Archives: BIO Investor Forum

T-Cell Therapies: Best Bets in Pushing Down the Cost Curve and Prioritizing Cancer Targets

New approaches in cancer immunology are achieving promising early-stage results through novel techniques for arming the body’s own t-cells to have greater impact on reducing tumors and preventing the spread of disease. CAR-T methods that extract, reengineer, and reintroduce a given patient’s t-cells provide highly personalized therapy but may be difficult to scale up. The interleukin enhancement approach motivates existing t-cells to be more effective and may be easier to deliver but have less pervasive Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

How to Pitch to Investors

To help biotechs wow the scores of venture investors attending the BIO Investor Forum conference (San Fran, Oct 7-8), BIO held a “How to Pitch to Investors” web panel featuring David Collier, M.D., Managing Director, CMEA Capital; CEO, Velocity Pharmaceutical Development, Joe Sum, Partner & Analyst, EcoR1 Capital, Adam Cutler, Managing Director, Trout Group, and Tony Tontat, Capital Access Advisors/Boston. The recording of this can’t-miss web panel is here: Here’s a recap of the first Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Gates to contribute $50M for Ebola response

admin-ajax

Bill Gates was on MSNBC’s Morning Joe to discuss the Gates Foundation’s contribution of $50 million to support emergency response to Ebola. Mr. Gates responded to criticism that the U.S. was initially slow to properly address the African crisis. He noted that it would be virtually impossible to respond much quicker to the unprecedented scale of the outbreak. He did call upon other countries to step up and dedicate resources as well. The most recent Read More >

Corporate, Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

BIO Investor Forum Company Snapshot: Syntrix Biosystems

SyntrixBioLogo_3D

1.     What is your company’s lead product or technology? Omnitram (O-desmethyltramadol) is a novel  oral analgesic developed by Syntrix that alleviates pain via a dual mechanism involving mu-opioid receptor activation and inhibition of the reuptake of norepinephrine.  Omnitram is in clinical development and has just completed a Phase 1b double-blind, placebo-controlled clinical trial (N=40) in experimental pain. 2.     What sets your company apart from competitors? Omnitram is a proprietary solution for pain relief that is Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , ,

Patient and Venture Philanthropy Groups Presenting at 2014 BIO Investor Forum

BIO’s alliance development team works to foster collaboration between the biotech industry and nonprofit disease foundations. In recent years, many nonprofit foundations have become more engaged in the drug development process – whether they have created clinical trial recruitment tools, established a disease registry, or funded emerging biotech companies. Recognizing the value of these initiatives to expedite research and drug development, BIO provides opportunities for venture philanthropies and patient organizations to connect with BIO members Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , ,